These data show that even though ASOs targeting APOE and TREM2 lead to transcriptional and phenotypical changes in human microglia 4 weeks after treatment, they are not able to alter amyloid pathology at the time point investigated here. The gene discussed is APOE; the disease is amyloidosis.